IL218417A - Niacin fatty acid couplings and their uses - Google Patents

Niacin fatty acid couplings and their uses

Info

Publication number
IL218417A
IL218417A IL218417A IL21841712A IL218417A IL 218417 A IL218417 A IL 218417A IL 218417 A IL218417 A IL 218417A IL 21841712 A IL21841712 A IL 21841712A IL 218417 A IL218417 A IL 218417A
Authority
IL
Israel
Prior art keywords
fatty acid
acid niacin
niacin conjugates
conjugates
fatty
Prior art date
Application number
IL218417A
Other languages
English (en)
Hebrew (he)
Other versions
IL218417A0 (en
Original Assignee
Catabasis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL218417(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Catabasis Pharmaceuticals Inc filed Critical Catabasis Pharmaceuticals Inc
Publication of IL218417A0 publication Critical patent/IL218417A0/en
Publication of IL218417A publication Critical patent/IL218417A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL218417A 2009-09-01 2012-03-01 Niacin fatty acid couplings and their uses IL218417A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23890309P 2009-09-01 2009-09-01
US30852410P 2010-02-26 2010-02-26
US31095210P 2010-03-05 2010-03-05
PCT/US2010/047262 WO2011028689A1 (en) 2009-09-01 2010-08-31 Fatty acid niacin conjugates and their uses

Publications (2)

Publication Number Publication Date
IL218417A0 IL218417A0 (en) 2012-04-30
IL218417A true IL218417A (en) 2017-09-28

Family

ID=43625772

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218417A IL218417A (en) 2009-09-01 2012-03-01 Niacin fatty acid couplings and their uses

Country Status (24)

Country Link
US (13) US8304551B2 (enExample)
EP (1) EP2473045B1 (enExample)
JP (1) JP5802209B2 (enExample)
KR (1) KR101685734B1 (enExample)
CN (1) CN102724877B (enExample)
AR (1) AR078151A1 (enExample)
AU (1) AU2010289683C1 (enExample)
BR (1) BR112012004677A2 (enExample)
CA (1) CA2772618C (enExample)
CL (1) CL2010000935A1 (enExample)
CR (1) CR20120167A (enExample)
DK (1) DK2473045T3 (enExample)
ES (1) ES2599626T3 (enExample)
GT (1) GT201200056A (enExample)
IL (1) IL218417A (enExample)
IN (1) IN2012DN02661A (enExample)
MX (1) MX2012002710A (enExample)
MY (1) MY158504A (enExample)
NI (1) NI201200038A (enExample)
NZ (1) NZ599067A (enExample)
RU (1) RU2569063C2 (enExample)
SG (2) SG10201500431SA (enExample)
TW (1) TWI519312B (enExample)
WO (1) WO2011028689A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
DK2473045T3 (en) 2009-09-01 2016-12-12 Catabasis Pharmaceuticals Inc Niacin-FATTY ACID CONJUGATES AND THEIR USES
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2949344A3 (en) 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
CA2847418A1 (en) * 2011-08-31 2013-03-07 Catabasis Pharmaceuticals, Inc. Fatty acid amides useful in the treatment of inflammatory disorders
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
EP2844257A4 (en) * 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
WO2013177536A2 (en) * 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2013187673A1 (ko) * 2012-06-11 2013-12-19 주식회사 휴메딕스 복합 비타민 컨쥬게이트 및 그를 포함하는 항산화제
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CN103007081B (zh) * 2012-11-27 2013-12-04 鞠法红 一种治疗非酒精性脂肪肝的中药组合物
WO2014083476A2 (en) * 2012-11-27 2014-06-05 Mahesh Kandula Compositions and methods for the treatment of metabolic and lipid disorders
WO2014087307A2 (en) * 2012-12-04 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
CN103012419B (zh) * 2012-12-20 2015-01-07 中国科学院深圳先进技术研究院 一种罗丹明b衍生物的合成方法
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
WO2014106804A2 (en) * 2013-01-04 2014-07-10 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014106805A2 (en) * 2013-01-05 2014-07-10 Mahesh Kandula Fatty acid conjugates and their uses
AU2014203872A1 (en) * 2013-01-07 2015-07-09 Catabasis Pharmaceuticals, Inc. Use of fatty acid niacin conjugates for treating diseases
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
WO2014122575A2 (en) * 2013-02-08 2014-08-14 Mahesh Kandula Fatty acid conjugates for the treatment of inflammation and metabolic diseases
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US11351139B2 (en) 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3068224A1 (en) * 2013-11-15 2016-09-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016130417A1 (en) * 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3801496A4 (en) 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. SUBSTANCES AND METHODS OF USE FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOL FATTY LIVER
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3873415A1 (en) 2018-11-02 2021-09-08 Unilever Global Ip Limited Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
EP4199895A4 (en) * 2020-08-18 2024-11-20 The Regents of The University of Michigan N-ACYL AMINO ACID PRODUCTS AND THEIR USES
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
US4169923A (en) 1974-10-15 1979-10-02 Paolo Ferruti High polymers containing nicotinic acid, process for their preparation and their use
CA1113486A (en) 1977-04-01 1981-12-01 Alfred Halpern Ultra-violet filtration with certain aminosalicylic acid esters
US4264517A (en) 1978-12-11 1981-04-28 G.D. Searle & Co. Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates
US4619938A (en) * 1984-03-21 1986-10-28 Terumo Kabushiki Kaisha Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors
IT1196348B (it) 1984-11-29 1988-11-16 Italfarmaco Spa Composti ad attivita'antiinfiammatoria
JPS61204171A (ja) 1985-03-06 1986-09-10 Terumo Corp ５−フルオロウラシル誘導体およびこれを含有する医薬製剤
JPH0248545B2 (ja) 1985-10-30 1990-10-25 Terumo Corp 33pirijinkarubonsann11okishidojudotaioyobikoreoganjusuruketsushobangyoshuyokuseizai
JPS62106019A (ja) * 1985-11-01 1987-05-16 Terumo Corp 抗高脂血症剤
JPS62106080A (ja) 1985-11-01 1987-05-16 Terumo Corp エタノ−ルアミン誘導体およびこれを含有する抗高脂血症剤
JPS62258362A (ja) * 1986-05-02 1987-11-10 Terumo Corp アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
US4670465A (en) 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH01121253A (ja) 1987-11-05 1989-05-12 Terumo Corp エタノールアミン誘導体包接化合物およびその製法
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9508023D0 (en) 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
CA2220091C (en) * 1995-05-01 2011-01-04 Scotia Holdings Plc Nicotinic acid esters and pharmaceutical compositions containing them
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
GB9622636D0 (en) 1996-10-30 1997-01-08 Scotia Holdings Plc Presentation of bioactives
US5728732A (en) 1996-11-27 1998-03-17 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters and retinoids
CA2285548C (en) 1997-04-04 2006-07-11 Pfizer Products Inc. Nicotinamide derivatives
WO2000008015A2 (en) 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
EP1153049B1 (en) 1999-01-29 2005-08-10 Amersham Biosciences KK Temperature-responsive polymer compound and process for producing the same
GB9930026D0 (en) 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
HUP0204262A2 (hu) 2000-01-31 2003-04-28 Pfizer Products Inc. Benzogyűrűvel kondenzált heterociklusos csoportot tartalmazó nikotinamid-származékok, továbbá e vegyületeket tartalmazó, a PDE4 izozimek szelektív gátlására adható gyógyászati készítmények
US6562995B1 (en) 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
KR100939243B1 (ko) 2001-01-19 2010-01-29 인스티튜트 오브 파마콜로지 앤드 톡시콜로지 아캐더미 오브 밀리터리 메디칼 사이언시스 피.엘.에이. 차이나 포타슘 채널의 기능을 조절하는 아민 유도체, 그의제조방법 및 용도
WO2002060875A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
AU2002353485B2 (en) 2001-12-04 2009-01-15 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US20040191278A1 (en) 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
US7226930B2 (en) * 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
US20050267091A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
US20060105021A1 (en) * 2004-09-24 2006-05-18 Remington Direct Lp Cholesterol-reducing liquid
CA2588166A1 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP1874301A4 (en) 2005-04-13 2009-05-06 Merck & Co Inc Niacin receptor agonists, compositions containing such compounds and treatment methods
WO2007116027A1 (en) 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
US20110123575A1 (en) 2008-06-02 2011-05-26 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
DK2315740T3 (en) 2008-07-08 2018-01-08 Catabasis Pharmaceuticals Inc Fatty Acid Acetylated Salicylates and Their Uses
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
DK2473045T3 (en) 2009-09-01 2016-12-12 Catabasis Pharmaceuticals Inc Niacin-FATTY ACID CONJUGATES AND THEIR USES
US9216224B2 (en) 2010-03-05 2015-12-22 Catabasis Pharmaceuticals, Inc. Fatty acid COX inhibitor derivatives and their uses
US20130045939A1 (en) 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
EP2949344A3 (en) 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
US20120252810A1 (en) 2011-04-04 2012-10-04 Catabasis Pharmaceuticals, Inc. Fatty acid non-flushing niacin derivatives and their uses
EP2844257A4 (en) 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
AU2014203872A1 (en) 2013-01-07 2015-07-09 Catabasis Pharmaceuticals, Inc. Use of fatty acid niacin conjugates for treating diseases
EP3068224A1 (en) 2013-11-15 2016-09-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates

Also Published As

Publication number Publication date
AR078151A1 (es) 2011-10-19
US8940903B2 (en) 2015-01-27
US20140249189A1 (en) 2014-09-04
AU2010289683C1 (en) 2014-10-16
US9238077B2 (en) 2016-01-19
CR20120167A (es) 2012-08-21
IL218417A0 (en) 2012-04-30
GT201200056A (es) 2015-02-11
US9278136B2 (en) 2016-03-08
SG178948A1 (en) 2012-04-27
NI201200038A (es) 2012-08-17
RU2012112461A (ru) 2013-10-10
US20120264791A1 (en) 2012-10-18
US8304552B2 (en) 2012-11-06
KR101685734B1 (ko) 2016-12-12
JP5802209B2 (ja) 2015-10-28
MY158504A (en) 2016-10-14
US20120252850A1 (en) 2012-10-04
USRE45261E1 (en) 2014-11-25
US20110053990A1 (en) 2011-03-03
US20150209439A1 (en) 2015-07-30
US20160346397A1 (en) 2016-12-01
US20180028674A1 (en) 2018-02-01
CA2772618A1 (en) 2011-03-10
CN102724877B (zh) 2015-05-13
US9486534B2 (en) 2016-11-08
US8765964B2 (en) 2014-07-01
US20120184585A1 (en) 2012-07-19
US8765963B2 (en) 2014-07-01
KR20120093183A (ko) 2012-08-22
US20140113940A1 (en) 2014-04-24
EP2473045A4 (en) 2013-11-20
TW201117826A (en) 2011-06-01
MX2012002710A (es) 2012-04-19
JP2013503872A (ja) 2013-02-04
CN102724877A (zh) 2012-10-10
BR112012004677A2 (pt) 2020-11-03
NZ599067A (en) 2014-04-30
WO2011028689A1 (en) 2011-03-10
ES2599626T3 (es) 2017-02-02
AU2010289683A1 (en) 2012-04-19
DK2473045T3 (en) 2016-12-12
AU2010289683B2 (en) 2014-06-12
EP2473045A1 (en) 2012-07-11
USRE46605E1 (en) 2017-11-14
USRE45275E1 (en) 2014-12-02
US8304551B2 (en) 2012-11-06
CA2772618C (en) 2018-08-21
CL2010000935A1 (es) 2011-04-15
TWI519312B (zh) 2016-02-01
US20140228413A1 (en) 2014-08-14
SG10201500431SA (en) 2015-03-30
IN2012DN02661A (enExample) 2015-09-11
EP2473045B1 (en) 2016-08-17
RU2569063C2 (ru) 2015-11-20

Similar Documents

Publication Publication Date Title
IL218417A0 (en) Fatty acid niacin conjugates and their uses
SG10201801503XA (en) e-POLYLYSINE CONJUGATES AND USE THEREOF
IL215765A0 (en) Prion-free nanoparticle compositions and methods
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
SG173666A1 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
GB0921001D0 (en) Products and uses
GB0901494D0 (en) Compositions and Methods
GB0910620D0 (en) Agents and uses thereof
PL389237A1 (pl) Stoisko handlowe
GB0907616D0 (en) Methods and compositions
GB0908498D0 (en) Compositions and methods
GB0909720D0 (en) Compositions and methods
GB0903913D0 (en) Compositions and methods
GB0916446D0 (en) Concept 21
GB0916452D0 (en) Concept 32
GB0916461D0 (en) Concept 38
GB0916462D0 (en) Concept 39
GB0916460D0 (en) Concept 37
GB0916447D0 (en) Concept 22
GB0916468D0 (en) Concept 47
GB0916449D0 (en) Concept 30
GB0916453D0 (en) Concept 33
GB0916463D0 (en) Concept 40
GB0916448D0 (en) Concept 23
GB0911961D0 (en) Concept 48

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed